Mild cognitive impairment in Parkinson's disease
Alison Jane Yarnall1, Lynn Rochester, David John Burn
1Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, Tyne and Wear NE4 5PL, UK. alison.yarnall@ncl.ac.uk
Abstract:
The concept of mild cognitive impairment (MCI) in the general population has received increased attention over recent years, and is associated with risk of progression to Alzheimer's disease. Within Parkinson's disease (PD), MCI (PD-MCI) is also now recognised to be relatively common, with certain subtypes predicting progression to Parkinson's disease dementia (PDD). Recently, criteria to better characterise PD-MCI and its subtypes have been produced by the Movement Disorder Society. In contrast to the population as a whole, where amnestic MCI is the most common subtype, non-amnestic PD-MCI dominates, with prominent executive and attention dysfunction. Although the pathophysiology of PD-MCI is poorly understood and encompasses both PD and non-PD pathology, it is most likely the result of a complex interaction between neurotransmitter dysfunction, synaptic pathology, protein aggregation and neuronal damage. Determining the factors that influence the progression of these pathologies in PD and the individuals at risk of ultimately developing PDD is critical for targeted intervention and drug discovery studies. Further work is required, however, to determine the significance of PD-MCI and also to validate the diagnostic criteria. This would be best delivered in the form of longitudinal studies in homogenous cohorts of PD participants, to allow prognostication and generalisation among the PD population. At the present time, no drug therapies are available for PD-MCI. Management includes screening for the disorder, excluding treatable causes of cognitive decline and cautious use of dopamine agonists and medications such as anticholinergics.
Insights
Parkinson's disease mild cognitive impairment (PD-MCI) is common, often non-amnestic, and predicts dementia. Further research is needed to validate diagnostic criteria and understand progression factors for targeted interventions.
Area of Science:
- Neurology
- Neuroscience
- Cognitive Science
Background:
- Mild cognitive impairment (MCI) is increasingly recognized in the general population and linked to Alzheimer's disease risk.
- Mild cognitive impairment in Parkinson's disease (PD-MCI) is common and certain subtypes predict progression to Parkinson's disease dementia (PDD).
- Movement Disorder Society criteria now exist to characterize PD-MCI and its subtypes.
Purpose of the Study:
- To review the current understanding of PD-MCI, including its characteristics and diagnostic criteria.
- To highlight the differences between general MCI and PD-MCI, particularly subtype prevalence.
- To emphasize the need for further research, including longitudinal studies, to understand PD-MCI progression and validate diagnostic tools.
Main Methods:
- Review of existing literature and diagnostic criteria for PD-MCI.
- Comparison of PD-MCI subtypes with general MCI subtypes.
- Discussion of potential pathophysiological mechanisms underlying PD-MCI.
Main Results:
- Non-amnestic PD-MCI, characterized by executive and attention dysfunction, is more prevalent than amnestic MCI in the general population.
- The pathophysiology of PD-MCI is complex, involving neurotransmitter dysfunction, synaptic pathology, protein aggregation, and neuronal damage.
- Currently, no specific drug therapies exist for PD-MCI.
Conclusions:
- PD-MCI is a significant clinical entity requiring further investigation to validate diagnostic criteria and understand progression.
- Longitudinal studies in homogenous Parkinson's disease cohorts are crucial for prognostication and generalizability.
- Current management focuses on screening, excluding treatable causes, and cautious medication use.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
01:24Parkinson Disease ll: Pathophysiology
01:24Parkinson Disease l: Introduction
01:22Dementia l: Introduction
01:29Alzheimer Disease l: Introduction